Citations

Citations to this article as recorded by  

• Identification of novel chemical scaffolds against kinase domain of cancer causing human epidermal growth factor receptor 2: a systemic chemoinformatic approach
  Faris Alrumaihi
  Journal of Biomolecular Structure and Dynamics.2024; 42(12): 6269.     CrossRef
• Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer
  Mariia Ivanova, Francesca Maria Porta, Marianna D’Ercole, Carlo Pescia, Elham Sajjadi, Giulia Cursano, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis, Elena Guerini-Rocco, Giuseppe Curigliano, Giuseppe Viale, Nicola Fusco
  Virchows Archiv.2024; 484(1): 3.     CrossRef
• Analytical Performance Evaluation of a 523-Gene Circulating Tumor DNA Assay for Next-Generation Sequencing–Based Comprehensive Tumor Profiling in Liquid Biopsy Samples
  Johannes Harter, Eleonora Buth, Janina Johaenning, Florian Battke, Maria Kopp, Henning Zelba, Martin Schulze, Jiri Koedding, Saskia Biskup
  The Journal of Molecular Diagnostics.2024; 26(1): 61.     CrossRef
• Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
  Camille Suydam, Fairouz Chibane, Nicole Brown, Madeleine Schlafly, Alicia H. Arnold, Intisar Ghleilib, Melissa Easley, Joseph White
  Annals of Surgical Oncology.2024; 31(1): 376.     CrossRef
• Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis
  Huiyue Li, Jennifer K. Plichta, Kan Li, Yizi Jin, Samantha M. Thomas, Fei Ma, Li Tang, Qingyi Wei, You-Wen He, Qichen Chen, Yuanyuan Guo, Yueping Liu, Jian Zhang, Sheng Luo
  Breast Cancer Research and Treatment.2024; 204(1): 89.     CrossRef
• Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer
  Jennifer L. Guerriero, Jia-Ren Lin, Ricardo G. Pastorello, Ziming Du, Yu-An Chen, Madeline G. Townsend, Kenichi Shimada, Melissa E. Hughes, Siyang Ren, Nabihah Tayob, Kelly Zheng, Shaolin Mei, Alyssa Patterson, Krishan L. Taneja, Otto Metzger, Sara M. Tol
  npj Breast Cancer.2024;[Epub]     CrossRef
• Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer
  Melissa Yuwono Tjota, Jeremy P Segal, Peng Wang
  The Journal of Applied Laboratory Medicine.2024; 9(1): 76.     CrossRef
• High contrast breast cancer biomarker semi-quantification and immunohistochemistry imaging using upconverting nanoparticles
  Sanathana Konugolu Venkata Sekar, Hui Ma, Katarzyna Komolibus, Gokhan Dumlupinar, Matthias J. Mickert, Krzysztof Krawczyk, Stefan Andersson-Engels
  Biomedical Optics Express.2024; 15(2): 900.     CrossRef
• HER2-low breast cancer and response to neoadjuvant chemotherapy: a population-based cohort study
  Ximena Baez-Navarro, Mieke R. van Bockstal, Agnes Jager, Carolien H.M. van Deurzen
  Pathology.2024; 56(3): 334.     CrossRef
• Fast-tracking drug development with biomarkers and companion diagnostics
  Noreen McBrearty, Devika Bahal, Suso Platero
  Journal of Cancer Metastasis and Treatment.2024;[Epub]     CrossRef
• Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression
  Gary Tozbikian, Savitri Krishnamurthy, Marilyn M. Bui, Michael Feldman, David G. Hicks, Shabnam Jaffer, Thaer Khoury, Shi Wei, Hannah Wen, Paula Pohlmann
  Archives of Pathology & Laboratory Medicine.2024; 148(2): 242.     CrossRef
• Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer
  Eliya Farah, Chantelle Carbonell, Devon J. Boyne, Darren R. Brenner, Jan-Willem Henning, Daniel Moldaver, Simran Shokar, Winson Y. Cheung
  Cancers.2024; 16(3): 518.     CrossRef
• Clinical Internal Dosimetry and Biodistribution of 177Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma
  Yoga S. Narwadkar, Rahul V. Parghane, Sudeep Sahu, Sangita Lad, Kamal Deep, Gaurav Wanage, Tejal Suralkar, Sharmila Banerjee, Sudeep Gupta, Sandip Basu, Rajendra A. Badwe
  Clinical Nuclear Medicine.2024; 49(4): e149.     CrossRef
• Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration
  Cristina Díaz del Arco, María Jesús Fernández Aceñero, Luis Ortega Medina
  International Journal of Molecular Sciences.2024; 25(5): 2649.     CrossRef
• The combined immunohistochemical expression of AMBRA1 and SQSTM1 identifies patients with poorly differentiated cutaneous squamous cell carcinoma at risk of metastasis: A proof of concept study
  Michael H. Alexander, William J. Cousins, Tom Ewen, Andrew P. South, Penny Lovat, Niki Stefanos
  Journal of Cutaneous Pathology.2024; 51(6): 450.     CrossRef
• Concordance between pathologists and between specimen types in detection of HER2-low breast carcinoma by immunohistochemistry
  Jing Wang, Esther Yoon, Savitri Krishnamurthy
  Annals of Diagnostic Pathology.2024; 70: 152288.     CrossRef
• Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial
  Lingzhou Zhao, Yan Xing, Changcun Liu, Shaofei Ma, Wenhua Huang, Zhen Cheng, Jinhua Zhao
  Breast Cancer Research.2024;[Epub]     CrossRef
• Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients
  Yibo Chen, Tianyi Zhang, Rui Zhang, Xuchen Cao
  Cancer Biotherapy and Radiopharmaceuticals.2024;[Epub]     CrossRef
• Clinicopathological and prognostic significance of VEGF, PDGF-B, and HER2/neu expression in gallbladder cancer
  Pooja Shukla, Kumudesh Mishra, Ratnakar Shukla, Ruchira Vishwakarma, Niraj Kumari, Narendra Krishnani, Anu Behari, Vinay K. Kapoor
  Journal of Cancer Research and Therapeutics.2024; 20(1): 349.     CrossRef
• Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer
  G. Curigliano, R. Dent, H. Earle, S. Modi, P. Tarantino, G. Viale, S.M. Tolaney
  ESMO Open.2024; 9(4): 102989.     CrossRef
• Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status
  Sei Na, Milim Kim, Yujun Park, Hyun Jung Kwon, Hee-Chul Shin, Eun-Kyu Kim, Mijung Jang, Sun Mi Kim, So Yeon Park
  Breast Cancer.2024; 31(4): 705.     CrossRef
• Impact of Neoadjuvant Chemotherapy (NAC) on Biomarker Expression in Breast Cancer
  Suji Lee, Jee Yeon Kim, So Jeong Lee, Chung Su Hwang, Hyun Jung Lee, Kyung Bin Kim, Jung Hee Lee, Dong Hoon Shin, Kyung Un Choi, Chang Hun Lee, Gi Yeong Huh, Ahrong Kim
  Medicina.2024; 60(5): 737.     CrossRef
• Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future
  Heike Aupperle-Lellbach, Alexandra Kehl, Simone de Brot, Louise van der Weyden
  Veterinary Sciences.2024; 11(5): 199.     CrossRef
• Clinical Validation of Artificial Intelligence–Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non–Small Cell Lung Cancer
  Hyojin Kim, Seokhwi Kim, Sangjoon Choi, Changhee Park, Seonwook Park, Sergio Pereira, Minuk Ma, Donggeun Yoo, Kyunghyun Paeng, Wonkyung Jung, Sehhoon Park, Chan-Young Ock, Se-Hoon Lee, Yoon-La Choi, Jin-Haeng Chung
  JCO Precision Oncology.2024;[Epub]     CrossRef
• Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer
  Qiu-Xiao Yu, Ping-Ying Fu, Chi Zhang, Li Li, Wen-Ting Huang
  World Journal of Gastrointestinal Surgery.2024; 16(5): 1395.     CrossRef
• Lipid nanoparticles-based RNA therapies for breast cancer treatment
  Luigia Serpico, Yuewen Zhu, Renata Faria Maia, Sumedha Sumedha, Mohammad-Ali Shahbazi, Hélder A. Santos
  Drug Delivery and Translational Research.2024;[Epub]     CrossRef
• Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges
  Natthawadee Laokulrath, Mihir Gudi, Syed Ahmed Salahuddin, Angela Phek Yoon Chong, Cristine Ding, Jabed Iqbal, Wei Qiang Leow, Benjamin Yongcheng Tan, Gary Tse, Emad Rakha, Puay Hoon Tan
  Histopathology.2024;[Epub]     CrossRef
• Comprehensive Immunohistochemical Analysis of Epithelial–Mesenchymal Transition Biomarkers in the Invasive Micropapillary Cancer of the Breast
  Ozden Oz, Funda Alkan Tasli, Resmiye Irmak Yuzuguldu, Baha Zengel, Demet Kocatepe Cavdar, Merih Guray Durak, Raika Durusoy, Pranshu Sahgal
  International Journal of Breast Cancer.2024;[Epub]     CrossRef
• Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies
  Simona Borstnar, Ivana Bozovic-Spasojevic, Ana Cvetanovic, Natalija Dedic Plavetic, Assia Konsoulova, Erika Matos, Lazar Popovic, Savelina Popovska, Snjezana Tomic, Eduard Vrdoljak
  Radiology and Oncology.2024; 58(2): 258.     CrossRef
• Peer‐to‐peer validation of Ki‐67 scoring in a pathology quality circle as a tool to assess interobserver variability: are we better than we thought?
  Marit Bernhardt, Leonie Weinhold, Christine Sanders, Oliver Hommerding, Jan‐Frederic Lau, Marieta Toma, Verena Tischler, Matthias Schmid, Tomasz Zienkiewicz, Ralf Hildenbrand, Peter Gerlach, Hui Zhou, Martin Braun, Gunnar Müller, Erich Sieber, Christian M
  APMIS.2024;[Epub]     CrossRef
• Novel engineered HER2 specific recombinant protein nanocages for targeted drug delivery
  Javad Kheshti, Mohammad Ahmadyousefi, Meysam Soleimani
  Molecular Biology Reports.2024;[Epub]     CrossRef
• Circulating C-reactive protein levels as a prognostic biomarker in breast cancer across body mass index groups
  J. B. Holm, E. Baggesen, D. Cronin-Fenton, J. Frystyk, J. M. Bruun, P. Christiansen, S. Borgquist
  Scientific Reports.2024;[Epub]     CrossRef
• Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer
  Elena Guerini-Rocco, Konstantinos Venetis, Giulia Cursano, Eltjona Mane, Chiara Frascarelli, Francesco Pepe, Mariachiara Negrelli, Edoardo Olmeda, Davide Vacirca, Alberto Ranghiero, Dario Trapani, Carmen Criscitiello, Giuseppe Curigliano, Christian Rolfo,
  Critical Reviews in Oncology/Hematology.2024; 201: 104427.     CrossRef
• The differences between pure and mixed invasive micropapillary breast cancer: the epithelial–mesenchymal transition molecules and prognosis
  Ozden Oz, Resmiye Irmak Yuzuguldu, Ayse Yazici, Demet Kocatepe Cavdar, Cengiz Yilmaz, Mucteba Ozturk, Hilal Duzel, Duygu Gurel
  Breast Cancer Research and Treatment.2024;[Epub]     CrossRef
• Surgical Management of the Axilla in HR+/HER2– Breast Cancer in the Z1071 Era: A Propensity Score-Matched Analysis of the National Cancer Database
  Vayda R. Barker, Samer A. Naffouje, Melissa A. Mallory, Susan A. Hoover, Christine Laronga
  Annals of Surgical Oncology.2023; 30(13): 8371.     CrossRef
• Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer
  Yuan Guo, Xiaotong Xie, Wenjie Tang, Siyi Chen, Mingyu Wang, Yaheng Fan, Chuxuan Lin, Wenke Hu, Jing Yang, Jialin Xiang, Kuiming Jiang, Xinhua Wei, Bingsheng Huang, Xinqing Jiang
  European Radiology.2023; 34(2): 899.     CrossRef
• Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
  Lan Deng, Le Zhao, Lifen Liu, Haomin Huang
  Open Life Sciences.2023;[Epub]     CrossRef
• HER2-low expression in patients with advanced or metastatic solid tumors
  B. Uzunparmak, C. Haymaker, G. Raso, S. Masciari, L. Wang, H. Lin, A. Gorur, B. Kirby, A.-M. Cimo, A. Kennon, Q. Ding, G. Urschel, Y. Yuan, G. Feng, Y. Rizvi, A. Hussain, C. Zhu, P. Kim, G. Abbadessa, V. Subbiah, T.A. Yap, J. Rodon, S.A. Piha-Paul, F. Mer
  Annals of Oncology.2023; 34(11): 1035.     CrossRef
• Data on 2D culture characterisation of potential markers in human HER2-positive breast cancer cell lines
  Son H. Pham, Lyn R. Griffiths, Rachel K. Okolicsanyi, Larisa M. Haupt
  Data in Brief.2023; 46: 108880.     CrossRef
• Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors
  Christiane Palm, Catherine E. Connolly, Regina Masser, Barbara Padberg Sgier, Eva Karamitopoulou, Quentin Simon, Beata Bode, Marianne Tinguely
  Diagnostics.2023; 13(1): 168.     CrossRef
• Gene amplification mutations originate prior to selective stress in Acinetobacter baylyi
  Jennifer A Herrmann, Agata Koprowska, Tesa J Winters, Nancy Villanueva, Victoria D Nikityuk, Feini Pek, Elizabeth M Reis, Constancia Z Dominguez, Daniel Davis, Eric McPherson, Staci R Rocco, Cynthia Recendez, Shyla M Difuntorum, Kelly Faeth, Mario D Lopez
  G3.2023;[Epub]     CrossRef
• Flow Rate-Independent Multiscale Liquid Biopsy for Precision Oncology
  Jie Wang, Robert Dallmann, Renquan Lu, Jing Yan, Jérôme Charmet
  ACS Sensors.2023; 8(3): 1200.     CrossRef
• Single-cell HER2 quantification via instant signal amplification in microdroplets
  Xiaoxian Liu, Yifan Zhu, Caoxin Li, Yanyun Fang, Jinna Chen, Fei Xu, Yanqing Lu, Perry Ping Shum, Ying Liu, Guanghui Wang
  Analytica Chimica Acta.2023; 1251: 340976.     CrossRef
• Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine
  Daniela Miladinova
  Frontiers in Molecular Biosciences.2023;[Epub]     CrossRef
• CORRELATION BETWEEN DIFFERENT CLINICOPATHOLOGICAL PARAMETERS AND MOLECULAR SUBTYPES OF FEMALE BREAST CARCINOMA IN SOUTH REGION OF IRAQ
  Yassir Alaa Muhammed Hassan Shubbar
  Wiadomości Lekarskie.2023; 76(1): 97.     CrossRef
• Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test
  Elham Sajjadi, Elena Guerini-Rocco, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis, Mariia Ivanova, Nicola Fusco
  Frontiers in Molecular Biosciences.2023;[Epub]     CrossRef
• Protective Effect of HER2 Gene Polymorphism rs24537331 in the Outcome of Canine Mammary Tumors
  Ana Canadas-Sousa, Marta Santos, Patrícia Dias-Pereira
  Animals.2023; 13(8): 1384.     CrossRef
• Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review
  Jin Wang, Dongying Liao, Xuemin Zhang, Changhong Miao, Kuang Chen
  Breast Cancer: Targets and Therapy.2023; Volume 15: 281.     CrossRef
• HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
  Marina Popović, Tajana Silovski, Marija Križić, Natalija Dedić Plavetić
  International Journal of Molecular Sciences.2023; 24(9): 8206.     CrossRef
• HER2-Low Breast Cancer—Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast
  Aditya Bardia, Giuseppe Viale
  Targeted Oncology.2023; 18(3): 313.     CrossRef
• Histopathological and immunohistochemical analysis of predictive and prognostic markers in spontaneous canine mammary cancer
  Vladimír Tancoš, Marcel Kovalik, Martin Levkut, Martina Bobrovská, Petra Kolenčíková, Ľubomír Straka, Zuzana Ševčíková, Ondřej Škor, Martina Antošová, Lukáš Plank, Keith L. Thoday
  Acta Veterinaria Brno.2023; 92(2): 143.     CrossRef
• Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study
  Timothy Qi, Yanguang Cao
  European Journal of Pharmaceutical Sciences.2023; 186: 106467.     CrossRef
• The Effect of HER2-Low Status on Pathological Complete Response and Survival in Triple-Negative Breast Cancer: A Systemic Review and Meta-Analysis
  Yakup Ergun, Baran Akagunduz, Cengiz Karacin, Sema Turker, Gokhan Ucar
  Clinical Breast Cancer.2023; 23(6): 567.     CrossRef
• Efficacy, toxicity and prognostic factors of pyrotinib‑involved neoadjuvant therapy in HER2‑positive breast cancer: A retrospective study
  Hao Wang, Hailing Cao, Zhiyun Guo
  Oncology Letters.2023;[Epub]     CrossRef
• Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
  Feng Ye, Saikat Dewanjee, Yuehua Li, Niraj Kumar Jha, Zhe-Sheng Chen, Ankush Kumar, Vishakha, Tapan Behl, Saurabh Kumar Jha, Hailin Tang
  Molecular Cancer.2023;[Epub]     CrossRef
• Weakly supervised bilayer convolutional network in segmentation of HER2 related cells to guide HER2 targeted therapies
  Ching-Wei Wang, Kun-Lin Lin, Hikam Muzakky, Yi-Jia Lin, Tai-Kuang Chao
  Computerized Medical Imaging and Graphics.2023; 108: 102270.     CrossRef
• Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods
  Francesca Maria Porta, Elham Sajjadi, Konstantinos Venetis, Chiara Frascarelli, Giulia Cursano, Elena Guerini-Rocco, Nicola Fusco, Mariia Ivanova
  Journal of Personalized Medicine.2023; 13(7): 1176.     CrossRef
• HER2 Equivocal (Score = 2+) Breast Carcinoma Cases Identified by Immunohistochemistry at a South African Hospital. What is the Impact of Fluorescent In Situ Hybridization Testing?
  Reena Dhansukh Mohanlal, Nikki Bouwer, Pascale Willem
  Applied Immunohistochemistry & Molecular Morphology.2023; 31(8): 555.     CrossRef
• Discordance of HER2 Expression and/or Amplification on Repeat Testing
  Timothy P. DiPeri, Kathleen Kong, Kaushik Varadarajan, Daniel D. Karp, Jaffer A. Ajani, Shubham Pant, Michael F. Press, Sarina A. Piha-Paul, Ecaterina E. Dumbrava, Funda Meric-Bernstam
  Molecular Cancer Therapeutics.2023; 22(8): 976.     CrossRef
• Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes
  Mariausilia Franchina, Cristina Pizzimenti, Vincenzo Fiorentino, Maurizio Martini, Giuseppina Rosaria Rita Ricciardi, Nicola Silvestris, Antonio Ieni, Giovanni Tuccari
  International Journal of Molecular Sciences.2023; 24(16): 12795.     CrossRef
• Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes
  Kuikui Jiang, Danyang Zhou, Fei Xu, Wen Xia, Qiufan Zheng, Qianyi Lu, Rongzhen Luo, Ruoxi Hong, Shusen Wang
  BMC Cancer.2023;[Epub]     CrossRef
• Single domain antibodies specific for HER2 dimerization domain effectively disrupts HER2 dimerization
  Ahmad Najafi, Reza Valadan, Hossein Asgarian-Omran, Alireza Rafiei, Mohsen Tehrani
  International Immunopharmacology.2023; 124: 110999.     CrossRef
• Récepteur du facteur de croissance épidermique HER2, tests utilisés pour rechercher son amplification dans le cancer du sein : principes et limites
  Imane Eliahiai, Mohammed Eljiar, Sanae Chaib, Jinane KHarmoum, Mariame Chraïbi
  Bulletin du Cancer.2023; 110(12): 1301.     CrossRef
• HER2 copy number determination in breast cancer using the highly sensitive droplet digital PCR method
  Beate Alinger-Scharinger, Cornelia Kronberger, Georg Hutarew, Wolfgang Hitzl, Roland Reitsamer, Klaassen-Federspiel Frederike, Martina Hager, Thorsten Fischer, Karl Sotlar, Heidi Jaksch-Bogensperger
  Virchows Archiv.2023;[Epub]     CrossRef
• Integrated Molecular Characterization of HER2-Low Breast Cancer Using Next Generation Sequencing (NGS)
  Jean-Louis Merlin, Marie Husson, Nassim Sahki, Pauline Gilson, Vincent Massard, Alexandre Harlé, Agnès Leroux
  Biomedicines.2023; 11(12): 3164.     CrossRef
• Design of a Ratiometric Plasmonic Biosensor for Herceptin Detection in HER2-Positive Breast Cancer
  Neda Shahbazi, Rouholah Zare-Dorabei, Seyed Morteza Naghib
  ACS Biomaterials Science & Engineering.2022; 8(2): 871.     CrossRef
• A highly sensitive nanobiosensor based on aptamer-conjugated graphene-decorated rhodium nanoparticles for detection of HER2-positive circulating tumor cells
  Mahdi Sadeghi, Soheila Kashanian, Seyed Morteza Naghib, Esfandyar Askari, Fateme Haghiralsadat, Davood Tofighi
  Nanotechnology Reviews.2022; 11(1): 793.     CrossRef
• Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
  Carrie S. Wynn, Shou-Ching Tang
  Cancer and Metastasis Reviews.2022; 41(1): 193.     CrossRef
• Electroanalytical overview: screen-printed electrochemical sensing platforms for the detection of vital cardiac, cancer and inflammatory biomarkers
  Robert D. Crapnell, Alejandro Garcia-Miranda Ferrari, Nina C. Dempsey, Craig E. Banks
  Sensors & Diagnostics.2022; 1(3): 405.     CrossRef
• FTO genotype was associated with breast cancer in HER2 negative patients
  Fateme Montazeri, Hossein Hatami, Soroor Fathi, Naeemeh Hasanpour Ardekanizadeh, Fatemeh Bourbour, Samira Rastgoo, Fatemeh Shafiee, Mohammad Esmail Akbari, Maryam Gholamalizadeh, Seyed Alireza Mosavi Jarrahi, Saeid Doaei
  Clinical Nutrition ESPEN.2022; 49: 495.     CrossRef
• Breast Cancer Human Epidermal Growth Factor Receptor 2 mRNA Molecular Testing Compared to Immunohistochemistry with Correlation to Neoadjuvant Therapy Response
  Mahmoud Behairy, Samia Mohamed Gabal, Mohamed Sherif Negm
  Open Access Macedonian Journal of Medical Sciences.2022; 10(A): 352.     CrossRef
• Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review
  Noortje Verschoor, Teoman Deger, Agnes Jager, Stefan Sleijfer, Saskia M. Wilting, John W.M. Martens
  Cancer Treatment Reviews.2022; 106: 102384.     CrossRef
• RETRACTED: Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients
  Hui Liu, Xiaoyan Hu, Lingyun Wang, Tao Du, Jing Feng, Ming Li, Lei Liu, Xiaofang Liu
  Frontiers in Surgery.2022;[Epub]     CrossRef
• Use of Radionuclide-Based Imaging Methods in Breast Cancer
  Betül Altunay, Agnieszka Morgenroth, Felix M. Mottaghy
  Seminars in Nuclear Medicine.2022; 52(5): 561.     CrossRef
• Functional regulations between genetic alteration-driven genes and drug target genes acting as prognostic biomarkers in breast cancer
  Li Wang, Lei Yu, Jian Shi, Feng Li, Caiyu Zhang, Haotian Xu, Xiangzhe Yin, Lixia Wang, Shihua Lin, Anastasiia Litvinova, Yanyan Ping, Shangwei Ning, Hongying Zhao
  Scientific Reports.2022;[Epub]     CrossRef
• Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
  Anastasia Alataki, Mitch Dowsett
  Endocrine-Related Cancer.2022; 29(8): R105.     CrossRef
• The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
  Olga D. Bragina, Sergei M. Deyev, Vladimir I. Chernov, Vladimir M. Tolmachev
  Acta Naturae.2022; 14(2): 4.     CrossRef
• Deriving tumor purity from cancer next generation sequencing data: applications for quantitative ERBB2 (HER2) copy number analysis and germline inference of BRCA1 and BRCA2 mutations
  Stephanie E. Siegmund, Danielle K. Manning, Phani K. Davineni, Fei Dong
  Modern Pathology.2022; 35(10): 1458.     CrossRef
• Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer
  Matti Aapro, Fatima Cardoso, Giuseppe Curigliano, Alexandru Eniu, Joseph Gligorov, Nadia Harbeck, Andreas Mueller, Olivia Pagani, Shani Paluch-Shimon, Elzbieta Senkus, Beat Thürlimann, Khalil Zaman
  The Breast.2022; 66: 145.     CrossRef
• Application of Fluorescence In Situ Hybridization Assisted by Fluorescence Microscope in Detection of Her2 Gene in Breast Cancer Patients
  Fang Lu, Tingting Zhou, Yan Liu, Liying Song, Bin Zhang, Yuyan Li, Sorayouth Chumnanvej
  Contrast Media & Molecular Imaging.2022; 2022: 1.     CrossRef
• High sensitivity label-free detection of HER2 using an Al–GaN/GaN high electron mobility transistor-based biosensor
  Shivanshu Mishra, Pharyanshu Kachhawa, Amber Kumar Jain, Rajiv Ranjan Thakur, Nidhi Chaturvedi
  Lab on a Chip.2022; 22(21): 4129.     CrossRef
• Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines
  B. R. Nagarjun, Biren Parikh, Manaswi Nareshkumar Patel, Pina J. Trivedi, Dharmesh M. Patel
  South Asian Journal of Cancer.2022; 11(04): 281.     CrossRef
• S‑phase fraction, lymph node status and disease staging as the main prognostic factors to differentiate between young and older patients with invasive breast carcinoma
  António Pinto, João Matos, Teresa Pereira, Giovani Silva, Saudade André
  Oncology Letters.2022;[Epub]     CrossRef
• Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling
  Alina Batzilla, Junyan Lu, Jarno Kivioja, Kerstin Putzker, Joe Lewis, Thorsten Zenz, Wolfgang Huber, James Gallo
  PLOS Computational Biology.2022; 18(8): e1010438.     CrossRef
• Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins
  O. D. Bragina, V. I. Chernov, S. M. Deyev, V. M. Tolmachev
  Bulletin of Siberian Medicine.2022; 21(3): 132.     CrossRef
• Molecular Pathology of Gastric Cancer
  Moonsik Kim, An Na Seo
  Journal of Gastric Cancer.2022; 22(4): 264.     CrossRef
• Loss of NECTIN1 triggers melanoma dissemination upon local IGF1 depletion
  Julien Ablain, Amira Al Mahi, Harriet Rothschild, Meera Prasad, Sophie Aires, Song Yang, Maxim E. Dokukin, Shuyun Xu, Michelle Dang, Igor Sokolov, Christine G. Lian, Leonard I. Zon
  Nature Genetics.2022; 54(12): 1839.     CrossRef
• Advanced diagnosis technologies for HER2 breast cancer markers
  Mengxue Zhang
  Highlights in Science, Engineering and Technology.2022; 14: 44.     CrossRef
• An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)
  Aleix Prat, Aditya Bardia, Giuseppe Curigliano, M. Elizabeth H. Hammond, Sibylle Loibl, Sara M. Tolaney, Giuseppe Viale
  JAMA Oncology.2022; 8(11): 1676.     CrossRef
• Development of T-cell engagers selective for cells co-expressing two antigens
  Danielle M. Dicara, Sunil Bhakta, Mary Ann Go, James Ziai, Ron Firestein, Bill Forrest, Chen Gu, Steven R. Leong, Genee Lee, Shang-Fan Yu, Andrew G. Polson, Nicholas J. Agard
  mAbs.2022;[Epub]     CrossRef
• The clinical significance of HER2 expression in DCIS
  Ioanna Akrida, Francesk Mulita
  Medical Oncology.2022;[Epub]     CrossRef
• Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2
  Rachel Occhiogrosso Abelman, Arielle Medford, Laura Spring, Aditya Bardia
  The Cancer Journal.2022; 28(6): 423.     CrossRef
• The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients
  Ugur Gezer, Abel J. Bronkhorst, Stefan Holdenrieder
  Diagnostics.2022; 12(12): 3042.     CrossRef
• Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
  Ye Yuan, Xumei Liu, Yi Cai, Wenyuan Li
  Systematic Reviews.2022;[Epub]     CrossRef
• Interactions dietary components with expression level of breast cancer-related genes
  Fatemeh Bourbour, Azam Pourtaheri, Khadijeh Abbasi, Naeemeh Hasanpour Ardekanizadeh, Maryam Gholamalizadeh, Azadeh Hajipour, Sepideh Abdollahi, Seyedeh Elaheh Bagheri, Mina Ahmadzadeh, Saeid Doaei, Arezoo Haghighian
  Egyptian Journal of Medical Human Genetics.2022;[Epub]     CrossRef
• HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging
  Betül Altunay, Agnieszka Morgenroth, Mohsen Beheshti, Andreas Vogg, Nicholas C. L. Wong, Hong Hoi Ting, Hans-Jürgen Biersack, Elmar Stickeler, Felix M. Mottaghy
  European Journal of Nuclear Medicine and Molecular Imaging.2021; 48(5): 1371.     CrossRef
• Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge
  Christian Jackisch, Patricia Cortazar, Charles E. Geyer, Luca Gianni, Joseph Gligorov, Zuzana Machackova, Edith A. Perez, Andreas Schneeweiss, Sara M. Tolaney, Michael Untch, Andrew Wardley, Martine Piccart
  Cancer Treatment Reviews.2021; 99: 102229.     CrossRef
• Histologic Patterns of Cutaneous Metastases of Breast Carcinoma: A Clinicopathologic Study of 232 Cases
  Shira Ronen, David Suster, Wei-Shen Chen, Natali Ronen, Sri Krishna C. Arudra, Celestine Trinidad, Doina Ivan, Victor G. Prieto, Saul Suster
  The American Journal of Dermatopathology.2021; 43(6): 401.     CrossRef
• Standardized pathology report for breast cancer
  Soo Youn Cho, So Yeon Park, Young Kyung Bae, Jee Yeon Kim, Eun Kyung Kim, Woo Gyeong Kim, Youngmee Kwon, Ahwon Lee, Hee Jin Lee, Ji Shin Lee, Jee Young Park, Gyungyub Gong, Hye Kyoung Yoon
  Journal of Pathology and Translational Medicine.2021; 55(1): 1.     CrossRef
• The impact of oral contraceptive use on breast cancer risk: State of the art and future perspectives in the era of 4P medicine
  R. Bonfiglio, M.L. Di Pietro
  Seminars in Cancer Biology.2021; 72: 11.     CrossRef
• The Co-Expression of Melanoma-Antigen Family a Proteins and New York Esophageal Squamous Cell Carcinoma-1 in Breast Cancer: A Pilot Study
  Yu-Xin Wang, Feng-Lian Li, Li-Xin Du, Jun-Fang Liu, Li-Gang Huo, Shu-Qing Li, Bin Tian
  Cancer Management and Research.2021; Volume 13: 6123.     CrossRef
• Targeting HER2 protein in individual cells using ICP-MS detection and its potential as prognostic and predictive breast cancer biomarker
  A. Fernández Asensio, M. Corte-Rodríguez, J. Bettmer, L.M. Sierra, M. Montes-Bayón, E. Blanco- González
  Talanta.2021; 235: 122773.     CrossRef
• Development of a 99mTc-Labeled Single-Domain Antibody for SPECT/CT Assessment of HER2 Expression in Breast Cancer
  Lingzhou Zhao, Changcun Liu, Yan Xing, Jin He, Jim O’Doherty, Wenhua Huang, Jinhua Zhao
  Molecular Pharmaceutics.2021; 18(9): 3616.     CrossRef
• WITHDRAWN: Nouvelles stratégies thérapeutiques dans les cancers du sein HER2-surexprimé
  Benoîte Mery, Philippe Toussaint, Pierre-Etienne Heudel, Armelle Dufresne, Mélodie Carbonnaux, Hélène Vanacker, Thomas Bachelot, Olivier Trédan
  Bulletin du Cancer.2021;[Epub]     CrossRef
• Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
  Emad A. Rakha, Islam M. Miligy, Cecily M. Quinn, Elena Provenzano, Abeer M. Shaaban, Caterina Marchiò, Michael S. Toss, Grace Gallagy, Ciara Murray, Janice Walshe, Ayaka Katayama, Karim Eldib, Nahla Badr, Bruce Tanchel, Rebecca Millican-Slater, Colin Purd
  British Journal of Cancer.2021; 124(11): 1836.     CrossRef
• Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes
  Catherine L. Wetzel, Thomas L. Sutton, Stuart Gardiner, Maryam Farinola, Nathalie Johnson, Jennifer R. Garreau
  Journal of Surgical Oncology.2021; 124(8): 1224.     CrossRef
• Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy
  Lun Li, Min Chen, Shuyue Zheng, Hanlu Li, Weiru Chi, Bingqiu Xiu, Qi Zhang, Jianjing Hou, Jia Wang, Jiong Wu
  Frontiers in Oncology.2021;[Epub]     CrossRef
• tRNA‐derived fragments: tRF‐Gly‐CCC‐046, tRF‐Tyr‐GTA‐010 and tRF‐Pro‐TGG‐001 as novel diagnostic biomarkers for breast cancer
  Yue Zhang, Zhao Bi, Xiaohan Dong, Miao Yu, Kangyu Wang, Xingguo Song, Li Xie, Xianrang Song
  Thoracic Cancer.2021; 12(17): 2314.     CrossRef
• Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3
  L. De Cock, J. Heylen, A. Wildiers, K. Punie, A. Smeets, C. Weltens, P. Neven, J. Billen, A. Laenen, H. Wildiers
  ESMO Open.2021; 6(4): 100203.     CrossRef
• Standardized Pathology Report for Breast Cancer
  Soo Youn Cho, So Yeon Park, Young Kyung Bae, Jee Yeon Kim, Eun Kyung Kim, Woo Gyeong Kim, Youngmee Kwon, Ahwon Lee, Hee Jin Lee, Ji Shin Lee, Jee Young Park, Gyungyub Gong, Hye Kyoung Yoon
  Journal of Breast Cancer.2021; 24(1): 1.     CrossRef
• Circular RNA circ-ERBB2 promotes HER2-positive breast cancer progression and metastasis via sponging miR-136-5p and miR-198
  Jin-xiu Zhong, Yun-yuan Kong, Rong-guang Luo, Guo-jin Xia, Wen-xing He, Xue-zhong Chen, Wei-wei Tan, Qing-jie Chen, Yu-yin Huang, Yan-xing Guan
  Journal of Translational Medicine.2021;[Epub]     CrossRef
• Nouvelles stratégies thérapeutiques dans les cancers du sein HER2-surexprimé
  Benoîte Mery, Philippe Toussaint, Pierre-Etienne Heudel, Armelle Dufresne, Mélodie Carbonnaux, Hélène Vanacker, Thomas Bachelot, Olivier Trédan
  Bulletin du Cancer.2021; 108(11): 11S8.     CrossRef
• HER2 alterations in non-small-cell lung cancer – Druggable or undruggable?
  SureshKumar Bondili, Ravindra Nandhana, Vanita Noronha, Swayamprabha Pawar, Nandini Menon, Omshree Shetty, Anuradha Chougule, Abhishek Mahajan, Rajiv Kumar, VijayM Patil, Amit Joshi, Kumar Prabhash
  Cancer Research, Statistics, and Treatment.2021; 4(2): 374.     CrossRef
• UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer
  Evgenii L. Guryev, Anita S. Smyshlyaeva, Natalia Y. Shilyagina, Evgeniya A. Sokolova, Samah Shanwar, Alexey B. Kostyuk, Alexander V. Lyubeshkin, Alexey A. Schulga, Elena V. Konovalova, Quan Lin, Indrajit Roy, Irina V. Balalaeva, Sergey M. Deyev, Andrei V.
  Molecules.2020; 25(18): 4302.     CrossRef
• Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
  Min Chong Kim, Su Hwan Kang, Jung Eun Choi, Young Kyung Bae
  Journal of Breast Cancer.2020; 23(5): 484.     CrossRef

Citations

Citations to this article as recorded by  

• Heterogeneity of primary and metastatic CAFs: From differential treatment outcomes to treatment opportunities (Review)
  Zixing Kou, Cun Liu, Wenfeng Zhang, Changgang Sun, Lijuan Liu, Qiming Zhang
  International Journal of Oncology.2024;[Epub]     CrossRef
• Expression of Selected miRNAs in Normal and Cancer-Associated Fibroblasts and in BxPc3 and MIA PaCa-2 Cell Lines of Pancreatic Ductal Adenocarcinoma
  Václav Mandys, Alexey Popov, Robert Gürlich, Jan Havránek, Lucie Pfeiferová, Michal Kolář, Jana Vránová, Karel Smetana, Lukáš Lacina, Pavol Szabo
  International Journal of Molecular Sciences.2023; 24(4): 3617.     CrossRef
• MicroRNAs and colorectal cancer: clinical potential and regulatory networks
  George Yiadom Osei, Joseph Adu-Amankwaah, Selina Koomson, Solomon Beletaa, Emmanuel Akomanin Asiamah, Cecilia Smith-Togobo, Siti Razila Abdul Razak
  Molecular Biology Reports.2023; 50(11): 9575.     CrossRef
• MicroRNA-552 expression in colorectal cancer and its clinicopathological significance
  Joon Im, Soo Kyung Nam, Hye Seung Lee
  Journal of Pathology and Translational Medicine.2021; 55(2): 125.     CrossRef
• Postoperative changes in plasma miR21‐5p as a novel biomarker for colorectal cancer recurrence: A prospective study
  Masahiro Fukada, Nobuhisa Matsuhashi, Takao Takahashi, Nobuhiko Sugito, Kazuki Heishima, Kazuhiro Yoshida, Yukihiro Akao
  Cancer Science.2021; 112(10): 4270.     CrossRef
• Differential expression of microRNAs in colorectal cancer: Different patterns between isolated cancer gland and stromal cells
  Ayaka Sato, Yasuko Fujita, Koki Otsuka, Akira Sasaki, Hiromu Suzuki, Takayuki Matsumoto, Tamotsu Sugai
  Pathology International.2020; 70(1): 21.     CrossRef
• High-Throughput Multiplex Immunohistochemical Imaging of the Tumor and Its Microenvironment
  Jiwon Koh, Yoonjin Kwak, Jin Kim, Woo Ho Kim
  Cancer Research and Treatment.2020; 52(1): 98.     CrossRef
• Tumor Tissue MIR92a and Plasma MIRs21 and 29a as Predictive Biomarkers Associated with Clinicopathological Features and Surgical Resection in a Prospective Study on Colorectal Cancer Patients
  Masahiro Fukada, Nobuhisa Matsuhashi, Takao Takahashi, Nobuhiko Sugito, Kazuki Heishima, Yukihiro Akao, Kazuhiro Yoshida
  Journal of Clinical Medicine.2020; 9(8): 2509.     CrossRef
• The promising role of noncoding RNAs in cancer-associated fibroblasts: an overview of current status and future perspectives
  Zengli Fang, Jin Xu, Bo Zhang, Wei Wang, Jiang Liu, Chen Liang, Jie Hua, Qingcai Meng, Xianjun Yu, Si Shi
  Journal of Hematology & Oncology.2020;[Epub]     CrossRef
• Altered miR-21, miRNA-148a Expression in Relation to KRAS Mutation Status as Indicator of Adenoma-Carcinoma Transitional Pattern in Colorectal Adenoma and Carcinoma Lesions
  Somayeh Igder, Javad Mohammadiasl, Pooneh Mokarram
  Biochemical Genetics.2019; 57(6): 767.     CrossRef
• Development and Validation of an Easy-to-Implement, Practical Algorithm for the Identification of Molecular Subtypes of Gastric Cancer: Prognostic and Therapeutic Implications
  Jiwon Koh, Keun-Wook Lee, Soo Kyung Nam, An Na Seo, Ji-Won Kim, Jin Won Kim, Do Joong Park, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
  The Oncologist.2019; 24(12): e1321.     CrossRef
• Prognostic Utility of Histological Growth Patterns of Colorectal Lung Oligometastasis
  Son Jae Yeong, Min Gyoung Pak, Hyoun Wook Lee, Seung Yeon Ha, Mee Sook Roh
  Journal of Pathology and Translational Medicine.2018; 52(2): 98.     CrossRef
• Effect of dietary components on miRNA and colorectal carcinogenesis
  Adewale Oluwaseun Fadaka, Babajide A. Ojo, Olusola Bolaji Adewale, Temitope Esho, Ashley Pretorius
  Cancer Cell International.2018;[Epub]     CrossRef
• Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer
  Sumi Yun, Yoonjin Kwak, Soo Kyung Nam, An Na Seo, Heung-Kwon Oh, Duck-Woo Kim, Sung-Bum Kang, Hye Seung Lee
  Cancer Research and Treatment.2018; 50(4): 1351.     CrossRef
• Mutation analysis of CTNNB1 gene and the ras pathway genes KRAS , NRAS , BRAF , and PIK3CA in eyelid sebaceous carcinomas
  Mi Jung Kwon, Eun Sook Nam, Seong Jin Cho, Hye-Rim Park, Soo Kee Min, Jinwon Seo, Ji-Young Choe
  Pathology - Research and Practice.2017; 213(6): 654.     CrossRef
• Exosomal miRNAs and miRNA dysregulation in cancer-associated fibroblasts
  Fengming Yang, Zhiqiang Ning, Ling Ma, Weitao Liu, Chuchu Shao, Yongqian Shu, Hua Shen
  Molecular Cancer.2017;[Epub]     CrossRef
• Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients
  Jiwon Koh, Chan-Young Ock, Jin Won Kim, Soo Kyung Nam, Yoonjin Kwak, Sumi Yun, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
  Oncotarget.2017; 8(16): 26356.     CrossRef